Ulcerative colitis

Takeda Supports the Canadian IBD Research Consortium's $1 Million Pioneer Grant for Second Year

Retrieved on: 
Tuesday, February 13, 2024

TORONTO, Feb. 13, 2024 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce its support of the Canadian Inflammatory Bowel Disease Research Consortium's (CIRC) $1 million PIONEER Grant in its second year.

Key Points: 
  • TORONTO, Feb. 13, 2024 /CNW/ - Takeda Canada Inc. (Takeda) is pleased to announce its support of the Canadian Inflammatory Bowel Disease Research Consortium's (CIRC) $1 million PIONEER Grant in its second year.
  • This grant, with Takeda contributing $500,000 of the $1,000,000 award, will continue to support high-quality, impactful Canadian clinical research to improve patient outcomes and quality of life for people living with inflammatory bowel disease (IBD).
  • "We are immensely proud of our research community, this program and are grateful for Takeda partnership and dedication to advancing research in Canada."
  • "The PIONEER Grant, established through $1,000,000 in support from Takeda, gives Canadian IBD researchers an amazing and truly unique opportunity to conduct practice changing investigator-initiated research.

Palisade Bio Provides Corporate Update and Reiterates Guidance

Retrieved on: 
Tuesday, February 13, 2024

Carlsbad, CA, Feb. 13, 2024 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal (GI) diseases, today provided a corporate update and reiterated upcoming milestones.

Key Points: 
  • “We continue to make significant development progress with PALI-2108, our lead program.
  • The program is providing us with a growing body of data that we find encouraging, including support for a precision medicine approach,” commented J.D.
  • Although smaller, we believe the reconstituted board better matches our stage of development while retaining ethnic and gender diversity.
  • PALI-2108 is an orally administered, locally acting colon-specific phosphodiesterase-4B (PDE4B) inhibitor prodrug in development for patients affected by UC.

EQS-News: Abivax announces presentation of four abstracts for obefazimod in ulcerative colitis and sponsorship of scientific symposium at the 19th Congress of European Crohn’s and Colitis Organization (ECCO)

Retrieved on: 
Tuesday, February 13, 2024

“We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.

Key Points: 
  • “We are delighted that all four submitted abstracts have been accepted for presentations at ECCO.
  • We look forward to scientific exchange with the IBD community at ECCO,” said Sheldon Sloan, M.D., M. Bioethics, Chief Medical Officer of Abivax.
  • (Germany), on February 23, 2024, at 7:15-8:15 a.m. CET in room A12.
  • The Symposium will be broadcasted live and is accessible publicly here .

Caregivers Cheer First Patients at New Intermountain Primary Children’s Hospital, Miller Family Campus in Lehi, Utah

Retrieved on: 
Monday, February 12, 2024

The Miller Family Campus’ Infusion Center opened for one day before the grand opening to give them the treatments they needed, closer to home.

Key Points: 
  • The Miller Family Campus’ Infusion Center opened for one day before the grand opening to give them the treatments they needed, closer to home.
  • Everyone at the new campus has been so amazing to work with!”
    The new Miller Family Campus is a full-service children’s hospital providing nearly all the same specialty pediatric services that patients receive at the Salt Lake Campus.
  • The Miller Family Campus is part of Intermountain Health’s Primary Promise to build the nation’s model health system for children.
  • For more information about the new Miller Family Campus in Lehi, visit primarychildrens.org/lehi .

Palisade Bio Announces Formation of Clinical Advisory Board with Appointments of Preeminent Key Opinion Leaders

Retrieved on: 
Thursday, February 8, 2024

Drs.

Key Points: 
  • Drs.
  • Sands and Rieder will be advising Palisade on the advancement of its product candidates from preclinical studies to clinical trials.
  • “We are committed to advancing the treatment landscape for Inflammatory Bowel Disease (IBD) and believe that the appointment of these preeminent key opinion leaders will assist in the development of a precision approach for IBD treatment,” commented J.D.
  • Finley, Chief Executive Officer of Palisade.

Bruce Sherman, Chairman and Principal Owner of the Miami Marlins, to Receive 2024 Horatio Alger Award

Retrieved on: 
Tuesday, February 6, 2024

WASHINGTON, Feb. 6, 2024 /PRNewswire/ -- Horatio Alger Association of Distinguished Americans, Inc., a nonprofit educational organization honoring the achievements of outstanding individuals and encouraging youth to pursue their dreams through higher education, today announced that Bruce S. Sherman, chairman and principal owner of the Miami Marlins, has been selected for membership in this prestigious organization. Mr. Sherman joins 10 other exceptional business, civic and cultural leaders from across North America in receiving 2024 honors. For more than 75 years, the Horatio Alger Award has been annually bestowed upon esteemed individuals who have succeeded despite facing adversities, and who have remained committed to higher education and charitable efforts in their communities. 

Key Points: 
  • In 2017, he became the chairman and principal owner of the Miami Marlins, a Major League Baseball team.
  • "It is our utmost honor to present the Horatio Alger Award to these 11 outstanding leaders who have exemplified perseverance, passion and a deep appreciation for higher education," said James F. Dicke II, chairman, Horatio Alger Association and 2015 Horatio Alger Award recipient.
  • Mr. Sherman and the Member Class of 2024 will be formally inducted into the Association on April 4-6, 2024, during the Association's annual Horatio Alger Award Induction Ceremonies in Washington, D.C.
  • For more information about Horatio Alger Association and its Member Class of 2024, please visit www.horatioalger.org and follow the organization on Facebook , X , LinkedIn and Instagram .

Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of an Oral Anti-Interleukin 12/23 Antibody (RT-111)

Retrieved on: 
Monday, February 5, 2024

ET / 5:30 a.m. PT –

Key Points: 
  • ET / 5:30 a.m. PT –
    SAN JOSE, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced positive topline results from its Phase 1 clinical study of RT-111, a RaniPill® capsule containing an ustekinumab biosimilar, CT-P43.
  • In the study, RT-111 was well-tolerated and delivered ustekinumab with high bioavailability.
  • “We are highly encouraged by the positive results from our Phase 1 study for RT-111 – our third successfully completed Phase 1 trial using RaniPill® technology.
  • To our knowledge, RT-111 is the first ever oral monoclonal antibody to achieve high bioavailability in humans,” said Talat Imran, Chief Executive Officer of Rani.

Boomerang Medical Awarded "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease" by the Crohn’s & Colitis Foundation

Retrieved on: 
Wednesday, January 31, 2024

Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” from the Crohn's & Colitis Foundation.

Key Points: 
  • Boomerang Medical, a women-led bioelectronic medicine company, received the Corporate Circle Award for "Promising Up-and-Comer in the Fight Against Ulcerative Colitis and Crohn’s Disease” from the Crohn's & Colitis Foundation.
  • This award, given for the first time to a medical device company, acknowledges Boomerang Medical's alignment with the Foundation’s mission to improve the lives of those affected by inflammatory bowel disease.
  • The award was presented at the Foundation's annual President’s Corporate Circle reception, held during the annual Crohn’s & Colitis Congress® on January 26, 2024.
  • Heather Simonsen, CEO of Boomerang Medical, commented on the significance of this recognition: “We are deeply honored to be acknowledged by the Crohn’s & Colitis Foundation with this award.

EQS-News: Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Retrieved on: 
Tuesday, January 30, 2024

Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024

Key Points: 
  • Abivax to host KOL Investor Event to review phase 2b clinical data and phase 3 trial design for obefazimod in patients with moderately to severely active ulcerative colitis on February 6, 2024
    The issuer is solely responsible for the content of this announcement.
  • The event will feature Marla Dubinsky, MD, and Parambir Dulai, MD.
  • Along with Abivax’s management, they will be discussing the unmet medical need and current treatment landscape for patients suffering from ulcerative colitis (UC).
  • He serves as the Director of GI Clinical Trials and Precision Medicine, as well as Director of the Digestive Health Foundation Biorepository.

EQS-News: Abivax provides 2024 strategic outlook and lays out key milestones over next 12 months

Retrieved on: 
Tuesday, January 30, 2024

Our US office has recently been opened and we have completed the recruitment of a very experienced team with a particular focus in the US.

Key Points: 
  • Our US office has recently been opened and we have completed the recruitment of a very experienced team with a particular focus in the US.
  • No new safety signals were detected in UC patients treated up to five years with oral, once-daily obefazimod.
  • Obefazimod follow-on candidate selection from miR-124 library: R&D work on potential follow-on drug candidates to be selected from Abivax’s compound library is ongoing.
  • Selection of the first follow-on drug candidate is expected in Q3 2024 to further strengthen the Abivax pipeline.